GSK 4108771A
Alternative Names: gE/gI SAM (LNP) Vaccine; gE/gI SAM (LNP) Vaccine - GSK; GSK-4108771A; Herpes simplex virus 2 vaccine - GSK; HSV 2 vaccine - GSKLatest Information Update: 28 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Herpes simplex virus type 2 infections
Most Recent Events
- 07 Mar 2022 Phase-I/II clinical trials in Herpes simplex virus type 2 infections (Prevention) in Australia (IM) (NCT05298254) (EudraCT 2021-003586-35)
- 07 Mar 2022 Phase-I/II clinical trials in Herpes simplex virus type 2 infections (Prevention) in Belgium (IM) (NCT05298254)
- 30 Apr 2021 Suspended - Phase-I for Herpes simplex virus type 2 infections (Prevention) in USA (IM) to assess new data received (NCT04762511)